Loading clinical trials...
Loading clinical trials...
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Conditions
Interventions
Naloxone Hydrochloride Lotion, 0.5%
Placebo Lotion
Locations
16
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
City of Hope
Duarte, California, United States
Stanford University
Palo Alto, California, United States
USSF Health Morsani Center for Advanced Healthcare
Tampa, Florida, United States
Cleveland Clinic Indian River Hospital
Vero Beach, Florida, United States
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
Start Date
January 1, 2017
Primary Completion Date
September 1, 2022
Completion Date
September 1, 2022
Last Updated
October 28, 2022
NCT05414500
NCT06207812
NCT06588868
NCT06716658
NCT06470451
NCT05680558
Lead Sponsor
Elorac, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions